EXTON, PA — Frontage Laboratories, Inc., a leading contract research organization (CRO), has made a significant stride in its global expansion strategy with the acquisition of Accelera S.r.l’s Bioanalytical and Drug Metabolism & Pharmacokinetics businesses. The move marks Frontage’s first operational base in continental Europe, signaling a new chapter in the company’s 23-year history.
Accelera, based in Nerviano, Lombardy, Italy, is a renowned CRO that forms part of the NMS Group S.p.A. The firm has carved out a niche for itself in providing discovery, preclinical studies, and clinical bioanalysis to a diverse range of healthcare stakeholders, including pharmaceutical and biotechnology companies and academic institutions.
Frontage CEO Dr. Abdul Mutlib expressed his enthusiasm about the acquisition, citing Accelera’s reputation for high-quality R&D services. “This strategic acquisition is a first step in establishing Frontage’s footprint in Europe,” he said. “Both existing Frontage and Accelera clients stand to benefit greatly from Frontage’s increasingly global platform.”
Dr. Song Li, Founder and Chairman of Frontage, echoed this sentiment. He highlighted the company’s long-standing goal to expand operations in Europe and emphasized the value of their relationship with the Accelera team in actualizing these plans.
Luca Leone, CEO of Accelera, also welcomed the partnership, painting it as a significant milestone in Accelera’s journey. “This unique occasion opens up new horizons for collaboration and growth,” he said, adding that the partnership aligns with their commitment to advancing research and providing innovative solutions in the European market and beyond.
The acquisition also brings benefits to Nerviano Medical Sciences, with CEO Hugues Dolgos praising the potential of the Accelera-Frontage collaboration. He predicts that the partnership will drive innovation and make a lasting difference in the drug discovery and development process.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.